A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

BACKGROUND: Patients with activating epidermal growth factor receptor (EGFR) mutations are highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported that approximately 15–30% of patients treated with EGFR-TKIs experience central nervous system (CNS) progression, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakuda, Kazushige, Yamaguchi, Hiroyuki, Kenmotsu, Hirotsugu, Fukuda, Minoru, Takeshita, Masafumi, Suetsugu, Takayuki, Kirita, Keisuke, Ebi, Noriyuki, Hataji, Osamu, Miura, Satoru, Chibana, Kenji, Okamoto, Isamu, Yoshimura, Kenichi, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki, Sugio, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195707/
https://www.ncbi.nlm.nih.gov/pubmed/32357848
http://dx.doi.org/10.1186/s12885-020-06874-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195707/
https://www.ncbi.nlm.nih.gov/pubmed/32357848
http://dx.doi.org/10.1186/s12885-020-06874-6

Ejemplares similares